Testing on Biopsy-Sized Specimens Allow Greater Utility in Breast Cancer
July 1, 2008
Precision Therapeutics has announced that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with pathologic complete response in breast cancer patients treated with neoadjuvant (pre-operative) chemotherapy. Data published in Anticancer Research show that the assay accurately predicted response to therapy 75% of the time. This study, done in conjunction with US Oncology, a leading cancer research and treatment network, represents the company's first publication in the breast cancer setting. Other major findings in the study addressed technical aspects of the assay, including the feasibility of performing the test on small amounts of tissue and the reproducibility of test results. Learn more at www.precisiontherapeutics.com.
« Cox Picks TOA to Enhance its Customer Service | | Carnegie Learning Adaptive Math Solutions Provides Supplemental Support »
